02/03/2021

Amgen’s Biosimilar RIABNI™ (rituximab-arrx) Now Available

Continuing our four decades of experience in biologics development, Amgen is proud to announce the availability of our latest biosimilar RIABNI™ (rituximab-arrx). Please click the link below to see full Prescribing Information, including Boxed WARNINGS:

RIABNI™ Prescribing Information 

The Wholesale Acquisition Cost (WAC) of RIABNI™ will be 23.7% lower than the reference product.  RIABNI^TM is being made available at a WAC of $716.80 per 100 mg and $3,584.00 per 500 mg single-dose vial, 23.7% less than the WAC for Rituxan^®, 15.2% less than the WAC for TRUXIMA^®, and matching the WAC for RUXIENCE^®.  At launch, RIABNI^TM is priced 16.7% below the current Rituxan^® Average Selling Price (ASP).

RIABNI™ will be available from both wholesalers and specialty distributors.

Additionally, the following Healthcare Common Procedure Coding System (HCPCS) and National Drug Codes (NDC) have been assigned:

RIABNI™:

• Hospital HCPCS = C9399 (unclassified drugs or biologics)
• Clinic HCPCS = J3590 (unclassified biologic)
• NDC 55513-224-01, 100 mg single-dose vial of RIABNI™
• NDC 55513-326-01, 500 mg single-dose vial of RIABNI™

RIABNI^TM is administered as an intravenous infusion.

RIABNI™ Product Fact Sheet.